Farmas USA

ATHX

MultiStem^® cell therapy product (the “MASTERS-2” study) has received a Final Scientific Advice positive opinion from the European Medicines Agency (“EMA”).  This represents EMA’s opinion that, upon success, the study should be sufficient to warrant approval for commercialization, which is in line with the U.S. Special Protocol Assessment and Fast Track Designation.  In Japan, Athersys’ partner, HEALIOS K.K. (“Healios”) is conducting the TREASURE study, evaluating MultiStem therapy for ischemic stroke, and has received a priority review designation under Sakigake from Japan’s Pharmaceutical and Medical Devices Agency.  The results from the TREASURE study, if needed, are acceptable for supporting the applications for registration, along with the results from the MASTERS-2 study, in both the U.S. and Europe

https://finance.yahoo.com/news/athersys-reports-alignment-key-regulators-100000822.html

athx

tenía alerta para entrar por debajo de 1.30 pero lleva 6 meses sin perder los 1.37 y sobre todo el suelo ha sido 1.4

HZNP

-- Second-Quarter 2017 Net Sales of $289.5 Million; Up 12 Percent, Above Expectations --
-- Second-Quarter 2017 Net Loss of $209.5 Million; Adjusted EBITDA of $127.0 Million, Above Expectations --
-- Second-Quarter 2017 GAAP Operating Cash Flow of $47.9 Million; Non-GAAP Operating Cash Flow of $86.4 Million --
-- Second-Quarter 2017 Net Sales of Rare Disease Medicines Increased 70 Percent --
-- Completed Acquisition of River Vision Development Corp., Adding Late-Stage Development Biologic Teprotumumab --
-- Completed Sale of EMEA Marketing Rights for PROCYSBI® and QUINSAIR^TM --
-- Increasing Full-Year 2017 Net Sales Guidance Range to $1.010 Billion to $1.045 Billion; Increasing Full-Year 2017 Adjusted EBITDA Guidance Range to $340 Million to $375 Million --

The Company had cash and cash equivalents of $554.3 million as of June 30, 2017.  

Total principal amount of debt outstanding as of June 30, 2017, was $2.023 billion, which was composed of $848 million in senior secured term loans due 2024; $475 million senior notes due 2023; $300 million senior notes due 2024; and $400 million exchangeable senior notes due 2022.  As of June 30, 2017, net debt was $1.469 billion.

Primary Care Business Unit:  Total second-quarter net sales for the primary care business unit were $117.4 million, a decrease of 22 percent compared to the second quarter of 2016, due to the implementation of the new contracting model with pharmacy benefit managers.  Second-quarter 2017 net sales improved sequentially over first-quarter 2017 net sales as a result of higher average net realized price (ANRP) and improved prescription demand.

https://finance.yahoo.com/news/horizon-pharma-plc-announces-second-110000041.html

me parto ... ha sido ver la new de HZNP y he puesto una orden de compra en 13,01 por si sonaba la flauta, de eso hace hora y pico y con el precio en 15 pavos ... y veo ahora que se ha hecho un dip hasta 13,03 ... jo jo casi ...si es que nunca se sabe ,,,

TEVA los 19$ que es el valor que me había marcado de primera entrada , están demasiado cerca , demasiado pronto....ahora toca examinar la municion y decidir a qué valores destinarla ....HZNP parece que se me escapa , pero NVAX está en un punto muy interesante para hacer una muy buena jugada...🤔

SLD 4 TEVA Dec15'17 15 PUT 0.60 USD AMEX 17:24:04 OptTrader 3.18

edito que puse el primer paquete

A mi tambien me parece pronto pero, es lo que hay. A ver los soportes como funcionan.

teva

Morgan Stanley ha visto tu linia en los 16: PT lowered to $16 from $36 at Morgan Stanley.

Y luego va y añaden lo siguiente, por si no había bastante miedo: Bear case PT of $9 assumes more severe generic Copaxone erosion and generic business earnings downside

dvax

veo cierta locura, en máximos anuales, van a cantar offering por la noche? Una cosa que no me hace mucha gracia es que sacaron los ER el día 2 y aún no hemos visto ni rastro del 10Q... No sé si es paranoia, pero normal no es...

TEVA

Haber si gira la HDP.....